This is an accessibility statement from Health Research Board.
Health Research Board takes the following measures to ensure accessibility of HRB National Drugs Library:
The Web Content Accessibility Guidelines (WCAG) defines requirements for designers and developers to improve accessibility for people with disabilities. It defines three levels of conformance: Level A, Level AA, and Level AAA. HRB National Drugs Library is partially conformant with WCAG 2.1 level AA. Partially conformant means that some parts of the content do not fully conform to the accessibility standard.
We welcome your feedback on the accessibility of HRB National Drugs Library. Please let us know if you encounter accessibility barriers on HRB National Drugs Library:
We try to respond to feedback within .
HRB National Drugs Library is designed to be compatible with the following assistive technologies:
HRB National Drugs Library is not compatible with:
Accessibility of HRB National Drugs Library relies on the following technologies to work with the particular combination of web browser and any assistive technologies or plugins installed on your computer:
These technologies are relied upon for conformance with the accessibility standards used.
Despite our best efforts to ensure accessibility of HRB National Drugs Library , there may be some limitations. Below is a description of known limitations, and potential solutions. Please contact us if you observe an issue not listed below.
Known limitations for HRB National Drugs Library:
Health Research Board assessed the accessibility of HRB National Drugs Library by the following approaches:
Other related evidence for HRB National Drugs Library is available at:
This Accessibility Statement is approved by:
Health Research Board
This statement was created on 6 December 2021 using the W3C Accessibility Statement Generator Tool.